STON2

Across TCGA pan-cancer cohorts, STON2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of STON2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where STON2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types STON2 is over-expressed in tumor, although a few such as LUAD and CCRCC show the opposite, repressed pattern.

LUAD, HNSC, and CCRCC are the cancer types where STON2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STON2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−0.776	<.001	9	view →
HNSC	All	II,III,IV	+0.281	.001	9	view →
CCRCC	All	II,III,IV	−0.239	.003	7	view →
PDAC	All	IV	−1.015	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

STON2–LUAD

Open the LUAD breakdown →